Investor Presentaiton

Median PFS in First-Line, Any-Line and Hepatic-Only MUM Observed Compelling Median Progression Free Survival with Encouraging Trend Any-Line MUM Swimlane Plot 00 First Response Progressive Disease Stable Disease End of Treatment Ongoing Treatment 10 12 14 16 18 20 22 24 Darovasertib + Crizotinib Phase 2 • Median Progression Free Survival First-Line (n=20): ~7 months Any-Line (n=63): ~7 months Median PFS has increased versus previously reported mPFS of ~5 months (n=35, September 2022*) Hepatic-Only (n=20): ~11 months 14 IDEAYA Data: preliminary analysis of unlocked database as of 03/08/2023 by investigator review, C1D1 cutoff as of 9/22/2022, based on 63 evaluable Any-Line MUM patients IDEAYA Press Release September 11, 2022 IDEAVA BIOSCIENCES 0 2 4 6 Months Since C1D1

View entire presentation